Floatz logo

Molgramostim

Acute Respiratory Distress Syndrome

Savara Inc.protein_peptidePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Acute Respiratory Distress Syndrome cohort.

Asset / SponsorPhaseRating
TRH
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phase 3BB
BETAMETHASONE
National Center for Research Resources (NCRR)
Phase 3BB
VITAMIN D
Prof. Dr. Jörg Leuppi
Phase 3BB
DEXAMETHASONE
National Center for Research Resources (NCRR)
Phase 3B
Tocilizumab
National Cancer Institute (NCI)
Phase 2CCC
Vasoactive Intestinal Peptide
Stony Brook University
Phase 1CC
Recombinant Human Keratinocyte Growth Factor-2 For Inhalation
Shanghai Zhongshan Hospital
Early Phase 1C
Oxygen
Evangelismos Hospital
N/AD

Same molecule, other indications

Molgramostim is also rated in:

cystic fibrosisDormant
CCC
Indicative ·
55 / 100
View asset →
cutaneous melanomaDormant
CCC
Indicative ·
55 / 100
View asset →
Mycobacterium Infections, NontuberculousDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →